Promoted Content
Promoted Content

Find Novel Gastroenterology Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HT-003

            Therapeutic Area: Gastroenterology Product Name: HT-003

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hoth Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 11, 2021

            Details:

            Fresh explants of ulcerative colitis and Crohn's disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Hatteras Venture

            Deal Size: $11.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing March 01, 2021

            Details:

            Artizan will use the proceeds to continue advancing the preclinical research and development of its lead program for inflammatory bowel disease (“IBD”), which is anticipated to enter the clinic in 2022, as well as to explore additional disease targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: GlaxoSmithKline

            Deal Size: $481.0 million Upfront Cash: $44.0 million

            Deal Type: Collaboration December 20, 2020

            Details:

            GSK licenses global rights to a portfolio of GPR35 agonists designed by Sosei Heptares using its StaR® technology and structure-based drug design platform. The licensed products includes an advanced lead preclinical drug as well as multiple differentiated back-up compounds.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adalimumab

            Therapeutic Area: Gastroenterology Product Name: PGN-001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 06, 2020

            Details:

            Progenity has two lead drug-device candidates utilizing the DDS technology, PGN-001, a high-concentration formulation of adalimumab, and PGN-600 a liquid formulation of tofacitinib, both under development for the treatment of ulcerative colitis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Allocetra

            Therapeutic Area: Gastroenterology Product Name: Allocetra

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            Upon issuance, the new patent will provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases comprising gout, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PN-235

            Therapeutic Area: Gastroenterology Product Name: JNJ-77242113

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 29, 2020

            Details:

            The two new candidates, PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186), are being developed as part of a portfolio strategy of discovering and developing oral IL-23 receptor antagonists.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BX002

            Therapeutic Area: Gastroenterology Product Name: BX002

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2020

            Details:

            The poster presentation details a phage therapy panel, comprised of phage directed against Klebsiella pneumoniae, showing a broad target host range and the potential to address carbapenem-resistant and extended spectrum beta-lactamase (ESBL)-producing bacteria.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SNSP003

            Therapeutic Area: Gastroenterology Product Name: SNSP003

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: CF Foundation

            Deal Size: $22.5 Million Upfront Cash: $14.0 million

            Deal Type: Funding October 20, 2020

            Details:

            The new funding will be used to advance preclinical development and early stage clinical trials for Synspira’s non-porcine enzyme replacement therapy, SNSP003.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALV-304

            Therapeutic Area: Gastroenterology Product Name: ALV-304

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: U.S. Department of Defense

            Deal Size: $3.3 million Upfront Cash: Undisclosed

            Deal Type: Funding October 05, 2020

            Details:

            The funds will support Alivio’s preclinical research and development activities to potentially enable the filing of an investigational new drug (IND) application for ALV-304.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RTX-1688

            Therapeutic Area: Gastroenterology Product Name: RTX-1688

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            Rodeo Therapeutics nominates Candidate RTX-1688, a first-in-class oral small molecule therapy for tissue regeneration and repair, with inflammatory bowel disease as the initial indication and platform potential in other disease settings .